查看购物车
  • Traditional Chinese
  • Japanese
  • Korean
体外诊断进行数量：2024-2029
市场调查报告书
商品编码
1550800

体外诊断进行数量：2024-2029

IVD Test Procedure Volumes, 2024-2029
出版日期: | 出版商: Kalorama Information | 英文 405 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

体外诊断（IVD）市场作为一个快速发展的市场，在新技术、不断变化的医疗保健支出以及快速成长的精准诊断需求的推动下，在2024年实现成长。

本报告调查了体外诊断的数量，并依类型、地区和国家分析了2024年至2029年的趋势。涵盖从自我检测到专业护理点（POC）、临床化学和血液学。

目次

第1章 执行摘要

第2章 简介

  • 概要
  • 业界动向
  • 新冠肺炎（COVID-19）
  • 人口动向
  • 世界人口与老化
  • 人员削减
  • 慢性疾病增加
  • 个人化医疗服务
  • 新传染病的威胁
  • 壁蝨媒传疾病（TBD）
  • 兹卡热
  • 恰加斯
  • 登革热
  • 伊波拉病毒
  • 屈公病
  • 中东呼吸道症候群冠状病毒（MERS-CoV）
  • 马堡病毒
  • SARS-CoV-2（COVID-19）
  • 猴痘
  • 新兴国家与市场

第3章 IVD检验环节

  • IVD 测试的趋势
  • 细分市场成长预测
  • POC 测试
  • 临床化学
  • 免疫测定
  • 质量分析（免疫）
  • 分子检测
  • 血液学
  • 凝固
  • 传统微生物学
  • 血液型
  • 组织学/细胞学
  • 细分产品销售

第4章 世界IVD市场

  • 一般
  • 北美
  • 米国
  • 加拿大
  • 墨西哥、中美洲和南美洲
  • 巴西
  • 墨西哥
  • 其他中美洲和南美洲
  • 西欧
  • 法国
  • 德国
  • 义大利
  • 西班牙
  • 英国
  • 其他西欧
  • 东欧
  • 俄罗斯
  • 其他东欧
  • 亚太地区
  • 中国
  • 日本
  • 其他亚洲国家和地区
  • 中东
  • 土耳其
  • 其他中东地区
  • 非洲

第5章 护理点（POC）技术

  • 全球 POC 测试数量（依测试类型）
  • POC 自测试
  • 传统血糖监测活动
  • 持续血糖监测
  • 怀孕和生育力检测
  • 凝血试验
  • 粪便潜血试验
  • 滥用药物测试
  • 幽门螺旋桿菌检测
  • 爱滋病毒检测
  • 感染症
  • 胆固醇测试
  • POC检定
  • 价格趋势

第6章 临床化学检测技术

  • 检查类型
  • 一般化学
  • 血气和电解质
  • 尿液测试
  • 临床化学产品的全球销售
  • 价格趋势

第7章 免疫测定技术

  • 技术
  • 标籤技术
  • 酵素免疫测定法
  • 萤光偏光免疫分析（FPIA）
  • 放射免疫测定法（RIA）
  • 测试技术与产品销售
  • 心臟标记
  • 肿瘤标记
  • 自体免疫疾病
  • 过敏症状
  • 甲状腺疾病
  • 蛋白质
  • 贫血
  • 不孕症测试
  • 治疗药物监测
  • 维生素D
  • 糖尿病/HbA1c
  • 滥用药物
  • 感染症
  • 机器
  • 价格趋势

第8章 分子测试技术

  • 检查类型
  • 测试技术
  • 感染症
  • 验血
  • 癌症
  • 移植匹配
  • 血栓形成性SNP
  • 遗传性疾病
  • 其他分子测试
  • 出生前
  • 分子 IVD 产品的全球销售
  • 价格趋势

第9章 实验室验血程序

  • 检查类型
  • 血液学产品的全球销售
  • 价格趋势

第10章 凝血检验技术

  • 检查类型
  • 混凝剂的全球销售
  • 价格趋势

第11章 微生物学检测技术

  • 检查类型
  • ID/AST 自动化面板和试剂
  • 手动面板和试剂
  • 血液培养
  • 显色培养基
  • 迅速微生物学的検査
  • 质量分析
  • 传统 IVD 微生物学产品的全球销售
  • ID/AST 组合与试剂
  • 血液培养
  • 显色培养基
  • 迅速微生物学的検査
  • 质量分析
  • 价格趋势

第12章 血型判定程序

  • 检查类型
  • 血型测定产品销售
  • 价格趋势

第13章 组织学/细胞学检测技术

  • 检查类型
  • 免疫组织化学
  • 原位杂交测试
  • 巴氏试验
  • 传统非巴氏染色
  • 循环肿疡细胞
  • 流式细胞仪
  • 组织学/细胞学 IVD 产品销售
  • 价格趋势

第14章 公司简介

  • Abbott Diagnostics
  • Core Lab
  • i-STAT Business
  • Becton, Dickinson and Company (BD)
  • bioMerieux Inc.
  • BioFire Diagnostics Business
  • Bio-Rad Laboratories, Inc.
  • Bruker Corporation
  • Danaher Corporation
  • Dexcom
  • DiaSorin
  • Exact Sciences
  • Hologic, Inc.
  • PANTHER Molecular System
  • Illumina
  • Natera
  • QuidelOrtho Corporation
  • The Solana Business
  • Revvity
  • Roche Diagnostics
  • Core Lab
  • Core Molecular
  • cobas Liat System
  • HPV
  • 血液银行
  • 移植医学
  • Siemens Healthineers
  • Sysmex Corporation
  • Thermo Fisher Scientific Inc
  • Werfen

联络我们

简介目录
Product Code: 24-025

Act Now - Be Prepared for Tomorrow's IVD Market

Don't miss your chance to leverage Kalorama Information's expert insights. Equip your business with the knowledge to anticipate changes, optimize product development, and maximize your strategies in the dynamic IVD landscape.

Ready to take action? Purchase the "IVD Test Procedure Volumes, 2024-2029" report today and secure your competitive advantage in this billion-dollar industry.

Kalorama Information's "IVD Test Procedure Volumes, 2024-2029" report provides a deep dive into the global trends shaping in vitro diagnostic (IVD) procedural volumes. Designed to complement Kalorama's comprehensive market analysis in The Worldwide Market for In Vitro Diagnostic (IVD) Tests, 17th Edition, this essential report delivers actionable data on the growth, challenges, and emerging opportunities in the IVD space.

As a rapidly evolving market, the IVD landscape in 2024 is set to thrive, driven by new technologies, evolving healthcare spending, and a surge in demand for precision diagnostics. Our report not only identifies the most significant procedural segments but also breaks down the impact of ongoing innovations.

With this detailed market research, you can stay ahead of industry developments and make informed business decisions. Whether you are looking to expand your product portfolio, explore new market segments, or refine your strategic approach, "IVD Test Procedure Volumes, 2024-2029" offers the data and insights you need to succeed.

Why Choose This Report?

  • Comprehensive Market Data
    • Gain an in-depth understanding of IVD procedural volumes by type, region, and country. From self-testing and professional point-of-care (POC) to clinical chemistry, hematology, and beyond-this report covers it all.
  • Unmatched Insights into Growth Opportunities
    • Identify high-growth segments by exploring emerging markets and the potential of precision medicine applications.
  • Forward-Looking Analysis
    • Understand the trends impacting the IVD market, including shifts in regulatory landscapes, new product developments, and changing disease profiles. This report provides a comprehensive forecast from 2024 to 2029.
  • Strategic Guidance for Industry Players
    • Discover how market dynamics, healthcare system trends, and cost pressures are shaping the future of IVD. Use these insights to develop strategies for product positioning, market entry, and growth.

Scope & Methodology

The report includes:

  • Global IVD Procedure Volumes by type, covering self and professional POC, clinical chemistry, immunoassay, molecular diagnostics, hematology, coagulation, microbiology, blood banking, and histology/cytology.
  • Regional and Country-Specific Data for IVD procedures and their projected growth rates.
  • Cost Analysis of various IVD tests to evaluate profitability and potential revenue streams.

Table of Contents

Chapter One: Executive Summary

  • IVD Procedure Volume Estimate and Forecast
    • Figure 1-1: Global IVD Procedure Volumes, 2024 and 2029 (in millions # volume)
  • Scope & Methodology
  • About Kalorama Information

Chapter Two: Introduction

  • Overview
  • Industry Trends
    • Table 2-1: Global IVD Procedural Volume & Product Sales (includes glucose tests), 2024-2029 (in millions # volume; $ million)
    • Figure 2-1: Global IVD Procedural Volume & Product Sales (includes glucose tests), 2024-2029 (in millions # volume; $ million)
  • COVID-19
  • Demographic Trends
  • Global Population and Aging
    • Figure 2-2: Global Fertility Rate vs. Population Size, 1950-2050 (billion)
    • Figure 2-3: Global Population Distribution, 2022
    • Table 2-2: Elderly Support Ratio in Various Countries, 2010 and 2050 (Australia; Brazil; Canada; China; China, Hong Kong SAR; France; Germany; India; Italy; Japan; Mexico; Saudi Arabia; Singapore; South Africa; Spain; Turkey; United Kingdom; United States; World)
  • Workforce Reduction
    • Table 2-3: Age Under 15 and Over 65, by Continent, 2020 (Africa, Asia, Europe, Latin America/Caribbean, North America, Oceania)
  • Increase in Chronic Diseases
    • Figure 2-4: Leading Causes of Death Globally, by Number of Deaths, 2021 (in millions)
  • Personalized Medicine
  • New Infectious Disease Threats
    • Table 2-4: Selected Companies Marketing Products Addressing Emerging Infectious Disease Threats
  • Tickborne Diseases (TBDs)
  • Zika
  • Chagas
  • Dengue
  • Ebola
  • Chikungunya
  • Middle East Respiratory Syndrome-Coronavirus (MERS-CoV)
  • Marburg
  • SARS-CoV-2 (COVID-19)
  • Monkeypox
    • Table 2-5: Selected FDA EUAs for Molecular Diagnostic Tests for Monkeypox
  • Emerging and Emerged Markets
    • Table 2-6: Market Potential, by Total Population and Percent Urban, 2023 (population in million) (Brazil; Canada; Chile; China; Colombia; Egypt; India; Malaysia; Mexico; Peru; Poland; Russia; South Africa; South Korea; Saudi Arabia; Turkey; Ukraine; United States; Vietnam)

Chapter Three: IVD Testing Segments

  • IVD Testing Trends
    • Table 3-1: IVD Procedural Volume including Blood Glucose Tests, by Item, 2024-2029 (millions) (Blood Grouping/Typing; Clinical Chemistry; Coagulation; Conventional Microbiology; Hematology; Histology/Cytology; Immunoassays; Mass Spectrometry [Immuno]; Mass Spectrometry [Micro]; Molecular; POC Professional Tests; POC Self Testing)
    • Figure 3-1: IVD Procedural Volume including Blood Glucose Tests, by Item, 2024 (millions) (Blood Grouping/Typing; Clinical Chemistry; Coagulation; Conventional Microbiology; Hematology; Histology/Cytology; Immunoassays; Mass Spectrometry [Immuno]; Mass Spectrometry [Micro]; Molecular; POC Professional Tests; POC Self Testing)
    • Figure 3-2: IVD Procedural Volume including Blood Glucose Tests, by Item, 2029 (millions) (Blood Grouping/Typing; Clinical Chemistry; Coagulation; Conventional Microbiology; Hematology; Histology/Cytology; Immunoassays; Mass Spectrometry [Immuno]; Mass Spectrometry [Micro]; Molecular; POC Professional Tests; POC Self Testing)
    • Table 3-2: IVD Procedural Volume including Blood Glucose Tests, Share by Item, 2024-2029 (%) (Blood Grouping/Typing; Clinical Chemistry; Coagulation; Conventional Microbiology; Hematology; Histology/Cytology; Immunoassays; Mass Spectrometry [Immuno]; Mass Spectrometry [Micro]; Molecular; POC Professional Tests; POC Self Testing)
    • Figure 3-3: IVD Procedural Volume including Blood Glucose Tests, Share by Item, 2024 (%) (Blood Grouping/Typing; Clinical Chemistry; Coagulation; Conventional Microbiology; Hematology; Histology/Cytology; Immunoassays; Mass Spectrometry [Immuno]; Mass Spectrometry [Micro]; Molecular; POC Professional Tests; POC Self Testing)
    • Figure 3-4: IVD Procedural Volume including Blood Glucose Tests, Share by Item, 2029 (%) (Blood Grouping/Typing; Clinical Chemistry; Coagulation; Conventional Microbiology; Hematology; Histology/Cytology; Immunoassays; Mass Spectrometry [Immuno]; Mass Spectrometry [Micro]; Molecular; POC Professional Tests; POC Self Testing)
    • Table 3-3: IVD Procedural Volume excluding Blood Glucose Tests, 2024-2029 (millions) (Blood Grouping/Typing; Clinical Chemistry; Coagulation; Conventional Microbiology; Hematology; Histology/Cytology; Immunoassays; Mass Spectrometry [Immuno]; Mass Spectrometry [Micro]; Molecular; POC Professional Tests; POC Self Testing)
    • Figure 3-5: IVD Procedural Volume excluding Blood Glucose Tests, 2024 (millions) (Blood Grouping/Typing; Clinical Chemistry; Coagulation; Conventional Microbiology; Hematology; Histology/Cytology; Immunoassays; Mass Spectrometry [Immuno]; Mass Spectrometry [Micro]; Molecular; POC Professional Tests; POC Self Testing)
    • Figure 3-6: IVD Procedural Volume excluding Blood Glucose Tests, 2029 (millions) (Blood Grouping/Typing; Clinical Chemistry; Coagulation; Conventional Microbiology; Hematology; Histology/Cytology; Immunoassays; Mass Spectrometry [Immuno]; Mass Spectrometry [Micro]; Molecular; POC Professional Tests; POC Self Testing)
    • Table 3-4: IVD Procedural Volume excluding Blood Glucose Tests, Share by Item, 2024-2029 (%) (Blood Grouping/Typing; Clinical Chemistry; Coagulation; Conventional Microbiology; Hematology; Histology/Cytology; Immunoassays; Mass Spectrometry [Immuno]; Mass Spectrometry [Micro]; Molecular; POC Professional Tests; POC Self Testing)
    • Figure 3-7: IVD Procedural Volume excluding Blood Glucose Tests, Share by Item, 2024 (%) (Blood Grouping/Typing; Clinical Chemistry; Coagulation; Conventional Microbiology; Hematology; Histology/Cytology; Immunoassays; Mass Spectrometry [Immuno]; Mass Spectrometry [Micro]; Molecular; POC Professional Tests; POC Self Testing)
    • Figure 3-8: IVD Procedural Volume excluding Blood Glucose Tests, Share by Item, 2029 (%) (Blood Grouping/Typing; Clinical Chemistry; Coagulation; Conventional Microbiology; Hematology; Histology/Cytology; Immunoassays; Mass Spectrometry [Immuno]; Mass Spectrometry [Micro]; Molecular; POC Professional Tests; POC Self Testing)
  • Segment Growth Projections
  • POC Testing
    • Table 3-5: POC Testing: IVD Procedural Volume and IVD Product Sales excluding Blood Glucose Tests, 2024-2029 (in millions # volume) ($ million) (POC Professional Tests; POC Self Testing)
    • Figure 3-9: POC Testing: IVD Procedural Volume and IVD Product Sales excluding Blood Glucose Tests, 2024-2029 (in millions # volume) ($ million) (POC Professional Tests; POC Self Testing)
  • Clinical Chemistry
    • Table 3-6: Clinical Chemistry: IVD Procedural Volume and IVD Product Sales excluding Blood Glucose Tests, 2024-2029 (in millions # volume) ($ million)
    • Figure 3-10: Clinical Chemistry: IVD Procedural Volume and IVD Product Sales excluding Blood Glucose Tests, 2024-2029 (in millions # volume) ($ million)
  • Immunoassays
    • Table 3-7: Immunoassays: IVD Procedural Volume and IVD Product Sales excluding Blood Glucose Tests, 2024-2029 (in millions # volume) ($ million)
    • Figure 3-11: Immunoassays: IVD Procedural Volume and IVD Product Sales excluding Blood Glucose Tests, 2024-2029 (in millions # volume) ($ million)
  • Mass Spectrometry (Immuno)
    • Table 3-8: Mass Spectrometry (Immuno): IVD Procedural Volume and IVD Product Sales excluding Blood Glucose Tests, 2024-2029 (in millions # volume) ($ million)
    • Figure 3-12: Mass Spectrometry (Immuno): IVD Procedural Volume and IVD Product Sales excluding Blood Glucose Tests, 2024-2029 (in millions # volume) ($ million)
  • Molecular Assays
    • Table 3-9: Molecular Assays: IVD Procedural Volume and IVD Product Sales excluding Blood Glucose Tests, 2024-2029 (in millions # volume) ($ million)
    • Figure 3-13: Molecular Assays: IVD Procedural Volume and IVD Product Sales excluding Blood Glucose Tests, 2024-2029 (in millions # volume) ($ million)
  • Hematology
    • Table 3-10: Hematology: IVD Procedural Volume and IVD Product Sales excluding Blood Glucose Tests, 2024-2029 (in millions # volume) ($ million)
    • Figure 3-14: Hematology: IVD Procedural Volume and IVD Product Sales excluding Blood Glucose Tests, 2024-2029 (in millions # volume) ($ million)
  • Coagulation
    • Table 3-11: Coagulation: IVD Procedural Volume and IVD Product Sales excluding Blood Glucose Tests, 2024-2029 (in millions # volume) ($ million)
    • Figure 3-15: Coagulation: IVD Procedural Volume and IVD Product Sales excluding Blood Glucose Tests, 2024-2029 (in millions # volume) ($ million)
  • Conventional Microbiology
    • Table 3-12: Conventional Microbiology: IVD Procedural Volume and IVD Product Sales excluding Blood Glucose Tests, 2024-2029 (in millions # volume) ($ million)
    • Figure 3-16: Conventional Microbiology: IVD Procedural Volume and IVD Product Sales excluding Blood Glucose Tests, 2024-2029 (in millions # volume) ($ million)
  • Blood Grouping/Typing
    • Table 3-13: Blood Grouping/Typing: IVD Procedural Volume and IVD Product Sales excluding Blood Glucose Tests, 2024-2029 (in millions # volume) ($ million)
    • Figure 3-17: Blood Grouping/Typing: IVD Procedural Volume and IVD Product Sales excluding Blood Glucose Tests, 2024-2029 (in millions # volume) ($ million)
  • Histology/Cytology
    • Table 3-14: Histology/Cytology: IVD Procedural Volume and IVD Product Sales excluding Blood Glucose Tests, 2024-2029 (in millions # volume) ($ million)
    • Figure 3-18: Histology/Cytology: IVD Procedural Volume and IVD Product Sales excluding Blood Glucose Tests, 2024-2029 (in millions # volume) ($ million)
  • Segment Product Sales
    • Table 3-15: IVD Product Sales including Blood Glucose Tests, 2024-2029 ($ million) (Blood Grouping/Typing; Clinical Chemistry; Coagulation; Conventional Microbiology; Hematology; Histology/Cytology; Immunoassays; Mass Spectrometry [Immuno]; Mass Spectrometry [Micro]; Molecular; POC Professional Tests; POC Self Testing)
    • Figure 3-19: IVD Product Sales including Blood Glucose Tests, 2024 ($ million) (Blood Grouping/Typing; Clinical Chemistry; Coagulation; Conventional Microbiology; Hematology; Histology/Cytology; Immunoassays; Mass Spectrometry [Immuno]; Mass Spectrometry [Micro]; Molecular; POC Professional Tests; POC Self Testing)
    • Figure 3-20: IVD Product Sales including Blood Glucose Tests, 2029 ($ million) (Blood Grouping/Typing; Clinical Chemistry; Coagulation; Conventional Microbiology; Hematology; Histology/Cytology; Immunoassays; Mass Spectrometry [Immuno]; Mass Spectrometry [Micro]; Molecular; POC Professional Tests; POC Self Testing)
    • Table 3-16: IVD Product Sales including Blood Glucose Tests, Share by Item, 2024-2029 (%) (Blood Grouping/Typing; Clinical Chemistry; Coagulation; Conventional Microbiology; Hematology; Histology/Cytology; Immunoassays; Mass Spectrometry [Immuno]; Mass Spectrometry [Micro]; Molecular; POC Professional Tests; POC Self Testing)
    • Figure 3-21: IVD Product Sales including Blood Glucose Tests, Share by Item, 2024 (%) (Blood Grouping/Typing; Clinical Chemistry; Coagulation; Conventional Microbiology; Hematology; Histology/Cytology; Immunoassays; Mass Spectrometry [Immuno]; Mass Spectrometry [Micro]; Molecular; POC Professional Tests; POC Self Testing)
    • Figure 3-22: IVD Product Sales including Blood Glucose Tests, Share by Item, 2029 (%) (Blood Grouping/Typing; Clinical Chemistry; Coagulation; Conventional Microbiology; Hematology; Histology/Cytology; Immunoassays; Mass Spectrometry [Immuno]; Mass Spectrometry [Micro]; Molecular; POC Professional Tests; POC Self Testing)
    • Table 3-17: IVD Product Sales excluding Blood Glucose Tests, 2024-2029 ($ million) (Blood Grouping/Typing; Clinical Chemistry; Coagulation; Conventional Microbiology; Hematology; Histology/Cytology; Immunoassays; Mass Spectrometry [Immuno]; Mass Spectrometry [Micro]; Molecular; POC Professional Tests; POC Self Testing)
    • Figure 3-23: IVD Product Sales excluding Blood Glucose Tests, 2024 ($ million) (Blood Grouping/Typing; Clinical Chemistry; Coagulation; Conventional Microbiology; Hematology; Histology/Cytology; Immunoassays; Mass Spectrometry [Immuno]; Mass Spectrometry [Micro]; Molecular; POC Professional Tests; POC Self Testing)
    • Figure 3-24: IVD Product Sales excluding Blood Glucose Tests, 2029 ($ million) (Blood Grouping/Typing; Clinical Chemistry; Coagulation; Conventional Microbiology; Hematology; Histology/Cytology; Immunoassays; Mass Spectrometry [Immuno]; Mass Spectrometry [Micro]; Molecular; POC Professional Tests; POC Self Testing)
    • Table 3-18: IVD Product Sales excluding Blood Glucose Tests, Share by Item, 2024-2029 (%) (Blood Grouping/Typing; Clinical Chemistry; Coagulation; Conventional Microbiology; Hematology; Histology/Cytology; Immunoassays; Mass Spectrometry [Immuno]; Mass Spectrometry [Micro]; Molecular; POC Professional Tests; POC Self Testing)
    • Figure 3-25: IVD Product Sales excluding Blood Glucose Tests, Share by Item, 2024 (%) (Blood Grouping/Typing; Clinical Chemistry; Coagulation; Conventional Microbiology; Hematology; Histology/Cytology; Immunoassays; Mass Spectrometry [Immuno]; Mass Spectrometry [Micro]; Molecular; POC Professional Tests; POC Self Testing)
    • Figure 3-26: IVD Product Sales excluding Blood Glucose Tests, Share by Item, 2029 (%) (Blood Grouping/Typing; Clinical Chemistry; Coagulation; Conventional Microbiology; Hematology; Histology/Cytology; Immunoassays; Mass Spectrometry [Immuno]; Mass Spectrometry [Micro]; Molecular; POC Professional Tests; POC Self Testing)

Chapter Four: Global IVD Markets

  • General
    • Table 4-1: IVD Procedural Volume including Blood Glucose Tests, by Region, 2024-2029 (millions) (Africa; Asia/Pacific [China, Japan, Other Countries & Territories]; Eastern Europe; Mexico, Central, & South America; Middle East; North America [United States; Canada]; Western Europe)
    • Figure 4-1: IVD Procedural Volume including Blood Glucose Tests, by Region, 2024-2029 (millions) (Africa; Asia/Pacific; Eastern Europe; Mexico, Central & South America; Middle East; North America; Western Europe)
    • Table 4-2: IVD Procedural Volume including Blood Glucose Tests, Share by Region, 2024-2029 (%) (Africa; Asia/Pacific [China, Japan, Other Countries & Territories]; Eastern Europe; Mexico, Central & South America; Middle East; North America [United States; Canada]; Western Europe)
    • Figure 4-2: IVD Procedural Volume including Blood Glucose Tests, Share by Region, 2024 (%) (Africa; Asia/Pacific; Eastern Europe; Mexico, Central & South America; Middle East; North America; Western Europe)
  • North America
    • Table 4-3: North America IVD Procedural Volume including Blood Glucose Tests and Market Share, 2024-2029 (millions) (%) (Canada, United States)
    • Figure 4-3: North America IVD Procedural Volume including Blood Glucose Tests, 2024-2029 (millions) (Canada, United States)
  • United States
  • Canada
  • Mexico, Central & South America
    • Table 4-4: Mexico, Central & South America IVD Procedural Volume including Blood Glucose Tests and Market Share, 2024-2029 (millions)
    • Figure 4-4: Mexico, Central & South America IVD Procedural Volume including Blood Glucose Tests, 2024-2029 (millions)
  • Brazil
  • Mexico
  • Other Central & South America
    • Argentina
    • Chile
    • Colombia
    • Peru
    • Venezuela
    • All Other Countries & Territories
  • Western Europe
    • Table 4-5: Western Europe IVD Procedural Volume including Blood Glucose Tests and Market Share, 2024-2029 (millions) (%)
    • Figure 4-5: Western Europe IVD Procedural Volume including Blood Glucose Tests, 2024-2029 (millions)
  • France
  • Germany
  • Italy
  • Spain
  • United Kingdom
  • Other Western Europe
    • Austria
    • Belgium
    • Denmark
    • Finland
    • Greece
    • Ireland
    • Norway
    • Netherlands
    • Portugal
    • Sweden
    • Switzerland
    • All Other Countries & Territories
  • Eastern Europe
    • Table 4-6: Eastern Europe IVD Procedural Volume including Blood Glucose Tests and Market Share, 2024-2029 (millions) (%)
    • Figure 4-6: Eastern Europe IVD Procedural Volume including Blood Glucose Tests, 2024-2029 (millions)
  • Russia
  • Other Eastern Europe
    • Czech Republic
    • Hungary
    • Poland
    • Romania
    • Ukraine
    • All Other Countries
  • Asia/Pacific
    • Table 4-7: Asia/Pacific IVD Procedural Volume including Blood Glucose Tests and Market Share, 2024-2029 (millions) (%) (China, Japan, Other Countries & Territories)
    • Figure 4-7: Asia/Pacific IVD Procedural Volume including Blood Glucose Tests, 2024-2029 (millions)
  • China
  • Japan
  • Other Asian Countries and Territories
    • Australia
    • Hong Kong
    • India
    • Indonesia
    • Malaysia
    • Pakistan
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam
    • New Zealand
    • All Other Countries & Territories
  • Middle East
    • Table 4-8: Middle East IVD Procedural Volume including Blood Glucose Tests and Market Share, 2024-2029 (millions) (%)
    • Figure 4-8: Middle East IVD Procedural Volume including Blood Glucose Tests, 2024-2029 (millions)
  • Turkey
  • Other Middle East
    • Iran
    • Iraq
    • Israel
    • Saudi Arabia
    • United Arab Emirates
    • All Other Countries
  • Africa
    • Table 4-9: Africa IVD Procedural Volume including Blood Glucose Tests and Market Share, 2024-2029 (millions) (%)
    • Figure 4-9: Africa IVD Procedural Volume including Blood Glucose Tests, 2024-2029 (millions)
    • Nigeria
    • South Africa
    • All Other Countries & Territories

Chapter Five: Point-of-Care (POC) Procedures

  • Global POC Procedure Volume by Test Type
    • Table 5-1: Total POC Procedural Volume & Product Sales including blood glucose tests, 2024-2029
    • Table 5-2: Total POC Procedural Volume & Product Sales excluding blood glucose tests, 2024-2029
    • Figure 5-1: Regional POC Procedure Volumes excluding blood glucose tests, 2024 (Europe, Japan, United States, Rest of World)
  • POC Self Tests
    • Table 5-3: POC Self-Test Procedural Volume, by Type, 2024-2029 (millions) (Cholesterol; Coagulation; Drugs of Abuse; Fecal Occult Blood; Glucose, Continuous; Glucose, Self; H. pylori; HIV; Infectious Disease [incl. COVID-19]; Pregnancy; Urinalysis; Other [TSH, Allergy, Autoimmune, etc.])
  • Traditional Blood Glucose Monitoring Activities
  • Continuous Blood Glucose Monitoring
  • Pregnancy and Fertility Testing
  • Coagulation Testing
  • Fecal Occult Blood Testing
  • Drugs of Abuse Testing
  • 1. Pylori Testing
  • HIV Testing
  • Infectious Disease
  • Cholesterol Testing
  • POC Urinalysis Testing
  • Other POC Self-Testing
  • POC Self-Testing Product Sales
    • Table 5-4: POC Self-Test Product Sales, by Type, 2024-2029 ($ million) (Cholesterol; Coagulation; Drugs of Abuse; Fecal Occult Blood; Glucose, Continuous; Glucose, Self; H. pylori; HIV; Infectious Disease [incl. COVID-19]; Pregnancy; Urinalysis; Other [TSH, Allergy, Autoimmune, etc.])
  • Pricing Trends
    • Table 5-5: POC Self-Test $ IVD Products Per Procedure, 2024-2029 (Cholesterol; Coagulation; Drugs of Abuse; Fecal Occult Blood; Glucose, Continuous; Glucose, Self; H. pylori; HIV; Infectious Disease [incl. COVID-19]; Pregnancy; Urinalysis; Other [TSH, Allergy, Autoimmune, etc.])
  • POC Professional Testing
    • Table 5-6: POC Professional Procedural Volume, by Type, 2024-2029 (Cardiac Markers; Cholesterol; Coagulation; Critical Care POC; Drugs of Abuse; Fecal Occult Blood; Fertility; Glucose; HbA1c POC; Hematology; Infectious Diseases; Urine; Others)
  • POC Professional Blood Glucose Testing Procedures
  • POC Professional Critical Care Testing
  • POC Fertility Testing
  • POC Professional Infectious Disease Testing
  • POC Professional Cardiac Marker Testing
  • POC Professional Cholesterol/Lipid Testing
  • POC Professional Coagulation Testing
  • POC Professional HbA1C Testing
  • POC Professional Hematology Testing
  • POC Professional Fecal Occult Blood Screening
  • POC Professional Drugs of Abuse Testing
  • POC Professional Urinalysis Testing
  • Other POC Professional Testing
  • POC IVD Product Sales
    • Table 5-7: POC Professional IVD Product Sales, by Type, 2024-2029 ($ million) (Cardiac Markers; Cholesterol; Coagulation; Critical Care POC; Drugs of Abuse; Fecal Occult Blood; Fertility; Glucose; HbA1c POC; Hematology; Infectious Diseases; Urine; Others)
  • Pricing Trends
    • Table 5-8: POC Professional $ IVD Products Per Procedure, by Type 2024-2029 (Cardiac Markers; Cholesterol; Coagulation; Critical Care POC; Drugs of Abuse; Fecal Occult Blood; Fertility; Glucose; HbA1c POC; Hematology; Infectious Diseases; Urine; Others)

Chapter Six: Clinical Chemistry Procedures

  • Table 6-1: Clinical Chemistry Procedural Volume, by Type, 2024-2029 (Blood Gas Analysis, General Chemistry, Urinalysis)
  • Figure 6-1: Regional Clinical Chemistry Procedure Volumes, 2024 (Asia Pacific, Europe, United States, Rest of World)
  • Types of Tests
  • General Chemistry
    • Enzymes
    • Glucose
    • Lipids
    • Proteins
    • Other Compounds
  • Blood Gases & Electrolytes
  • Urinalysis
  • Global Sales of Clinical Chemistry Products
    • Table 6-2: Clinical Chemistry Product Sales, by Type, 2024-2029 ($ million) (Blood Gas Analysis; General Chemistry; Urinalysis)
  • Pricing Trends
    • Table 6-3: Clinical Chemistry $ IVD Product Sales Per Procedure, 2024-2029 (Blood Gas Analysis; General Chemistry; Urinalysis)

Chapter Seven: Immunoassay Procedures

  • Technologies
  • Labeling Techniques
  • Enzyme Immunoassays
  • Fluorescence Polarization Immunoassays (FPIAs)
  • Radioimmunoassays (RIAs)
    • Table 7-1: Immunoassay Procedural Volume, by Type, 2024-2029 (Allergy; Anemia; Autoimmune; Cardiac Markers; Diabetes/HbA1c; Fertility; Infectious Disease; Mass Spectrometry; Proteins; Therapeutic Drugs; Thyroid; Tox/Drug of Abuse; Tumor Markers; Vitamin D; Others)
    • Figure 7-1: Regional Immunoassay Procedure Volumes, 2024
  • Testing Procedures & Product Sales
    • Table 7-2: Immunoassay Product Sales, by Type, 2024-2029 ($ million) (Allergy; Anemia; Autoimmune; Cardiac Markers; Diabetes/HbA1c; Fertility; Infectious Disease; Mass Spectrometry; Proteins; Therapeutic Drugs; Thyroid; Tox/Drug of Abuse; Tumor Markers; Vitamin D; Others)
  • Cardiac Markers
  • Tumor Markers
  • Autoimmune Conditions
  • Allergy Conditions
  • Thyroid Conditions
  • Proteins
    • Alzheimer's Disease
  • Anemia
  • Fertility Testing
  • Therapeutic Drug Monitoring
  • Vitamin D
  • Diabetes/HbA1c
  • Drugs of Abuse
  • Infectious Diseases
    • Table 7-3: Immunoassay Infectious Disease Procedural Volume, by Type, 2024-2029 (HAI; Hepatitis; HIV; Resp; STD; ToRCH; Other)
    • Table 7-4: Immunoassay Infectious Disease Product Sales, by Type, 2024-2029 ($ million) (HAI; Hepatitis; HIV; Resp; STD; ToRCH; Other)
  • Instruments
  • Pricing Trends
    • Table 7-5: Immunoassay $ Product Sales Per Procedure, by Type, 2024-2029 (Allergy; Anemia; Autoimmune; Cardiac Markers; Diabetes/HbA1c; Fertility; Infectious Disease; Mass Spectrometry; Proteins; Therapeutic Drugs; Thyroid; Tox/Drug of Abuse; Tumor Markers; Vitamin D; Others)

Chapter Eight: Molecular Testing Procedures

  • Table 8-1: Molecular Assay Procedural Volume, by Type, 2024-2029 (millions) (Molecular - Other; Molecular Assays - Oncology; Molecular Blood Bank; Molecular Histology - Non Cancer; Molecular Histology - Cancer; Molecular HPV; Molecular Infectious Disease; Molecular Inherited Diseases; Molecular PT/INR [thrombophilia SNP tests]; Molecular Transplant Testing [HLA] Tissue Typing; Prenatal)
  • Figure 8-1: Regional Molecular Assay Procedure Volumes, 2024 (Asia Pacific, Europe, United States, Rest of World)
  • Types of Tests
  • Testing Technologies
  • Infectious Diseases
    • Table 8-2: Molecular Assay Infectious Disease Procedural Volume, by Type, 2024-2029 (COVID; GC/Chlamydia; HAI; Hepatitis; HIV; Mycobacteria/TB; Respiratory non-COVID; Other)
  • Blood Screening
  • Cancer
  • Transplant Matching
  • Thrombophilia SNPs
  • Inherited Diseases
  • Other Molecular Tests
  • Prenatal
  • Global Sales of Molecular IVD Products
    • Table 8-3: Molecular Assay Product Sales, by Type, 2024-2029 ($ million) (Molecular - Other; Molecular Assays - Oncology; Molecular Blood Bank; Molecular Histology - Non Cancer; Molecular Histology - Cancer; Molecular HPV; Molecular Infectious Disease; Molecular Inherited Diseases; Molecular PT/INR [thrombophilia SNP tests]; Molecular Transplant Testing [HLA] Tissue Typing; Prenatal)
    • Table 8-4: Molecular Assay Infectious Disease Product Sales, by Type, 2024-2029 ($ million) (COVID; GC/Chlamydia; HAI; Hepatitis; HIV; Mycobacteria/TB; Respiratory non-COVID; Other)
  • Pricing Trends
    • Table 8-5: Molecular Assays $ Products per Procedure, by Type, 2024-2029 (Molecular - Other; Molecular Assays - Oncology; Molecular Blood Bank; Molecular Histology - Non Cancer; Molecular Histology - Cancer; Molecular HPV; Molecular Infectious Disease; Molecular Inherited Diseases; Molecular PT/INR [thrombophilia SNP tests]; Molecular Transplant Testing [HLA] Tissue Typing; Prenatal)

Chapter Nine: Laboratory-Based Hematology Procedures

  • Table 9-1: Laboratory-Based Hematology Procedural Volume, by Type, 2024-2029 (Complete Blood Count; Other Hematology Tests)
  • Figure 9-1: Regional Laboratory-Based Hematology Procedure Volumes, 2024 (Asia Pacific, Europe, United States, Rest of World)
  • Types of Tests
  • Global Sales of Hematology Products
    • Table 9-2: Laboratory-Based Hematology Product Sales, by Type, 2024-2029 ($ million) (Complete Blood Count; Other Hematology Tests)
  • Pricing Trends
    • Table 9-3: Hematology $ Product Sales Per Procedure, by Type, 2024-2029 (Complete Blood Count, Other Hematology Tests)

Chapter Ten: Coagulation Testing Procedures

  • Table 10-1: Coagulation Procedural Volume, 2024-2029 (D-dimer, PT/INR)
  • Figure 10-1: US/ROW Coagulation Procedure Volumes, 2024 (Asia Pacific, Europe, North America, Rest of World)
  • Types of Tests
  • Global Sales of Coagulation Products
    • Table 10-2: Coagulation Product Sales, 2024-2029 ($ million) (D-dimer, PT/INR)
  • Pricing Trends
    • Table 10-3: Coagulation $ Products per Procedure, 2024-2029 (D-dimer, PT/INR)

Chapter Eleven: Microbiology Procedures

  • Table 11-1: Conventional Microbiology Procedural Volume, by Type, 2024-2029 (Blood Culture; Chromogenic Media; ID/AST Automated; ID/AST Panels; Mass Spectrometry; Rapid Microbiology)
  • Figure 11-1: Regional Microbiology Procedure Volumes, 2024 (Asia Pacific, Europe, North America, Rest of World)
  • Types of Tests
  • ID/AST Automated Panels & Reagents
  • Manual Panels & Reagents
  • Blood Culture
  • Chromogenic Media
  • Rapid Microbiological Tests
  • Mass Spectrometry
  • Global Sales of Conventional IVD Microbiology Products
  • ID/AST Panels & Reagents
  • Blood Culture
  • Chromogenic Media
  • Rapid Microbiological Tests
  • Mass Spectrometry
    • Table 11-2: Conventional Microbiology Product Sales, by Type, 2024-2029 ($ million) (Blood Culture; Chromogenic Media; ID/AST Automated; ID/AST Panels; Mass Spectrometry; Rapid Microbiology)
  • Pricing Trends
    • Table 11-3: Conventional Microbiology $ Product Sales Per Procedures, by Type, 2024-2029
    • (Blood Culture; Chromogenic Media; ID/AST Automated; ID/AST Panels; Mass Spectrometry; Rapid Microbiology)

Chapter Twelve: Blood Grouping/Typing Procedures

  • Table 12-1: Blood Grouping/Typing Procedure Volumes, 2024-2029
  • Figure 12-1: Regional Blood Grouping/Typing Procedure Volumes, 2024 (Asia Pacific, Europe, North America, Rest of World)
  • Types of Tests
  • Blood Grouping/Typing Product Sales
    • Table 12-2: Blood Grouping/Typing Product Sales, 2024-2029 ($ million)
  • Pricing Trends
    • Table 12-3: Blood Grouping/Matching $ Product Sales/Procedure, 2024-2029

Chapter Thirteen: Histology/Cytology Procedures

  • Table 13-1: Histology/Cytology Procedural Volume, by Type, 2024-2029 (CTCs; Flow Cytometry; Immunohistochemistry; In situ Hybridization; Pap Tests; Traditional non-Pap Stains)
  • Figure 13-1: Regional Histology/Cytology Procedure Volumes, 2024 (Asia Pacific, Europe, North America, Rest of World)
  • Types of Tests
  • Immunohistochemistry Tests
  • In Situ Hybridization Tests
  • Pap Tests
  • Traditional Non-Pap Stains
  • Circulating Tumor Cells
  • Flow Cytometry
  • Histology/Cytology IVD Product Sales
    • Table 13-2: Histology/Cytology Product Sales, by Type, 2024-2029 ($ million) (CTCs; Flow Cytometry; Immunohistochemistry; In situ Hybridization; Pap Tests; Traditional non-Pap Stains)
  • Pricing Trends
    • Table 13-3: Histology/Cytology $ Product Sales Per Procedure, by Type, 2024-2029

Chapter Fourteen: Company Profiles

  • Table 14-1: Revenues of Selected Top 20 IVD Companies, 2023 and estimated 2024 ($ million) (Abbott Diagnostics; Agilent; Becton Dickinson; bioMerieux; Bio-Rad Laboratories; Bruker - CALID; Danaher; Dexcom; DiaSorin; Exact Sciences; Hologic; Illumina; Natera; QuidelOrtho; Revvity; Roche Diagnostics; Siemens Healthineers; Sysmex Corporation; Thermo Fisher Scientific; Werfen)
  • Abbott Diagnostics
  • Recent Revenue History
    • Table 14-2: Abbott Diagnostic Revenues, 2017-2023 (million $)
  • Core Lab
  • Hematology
  • Blood Banking
  • Infectious Diseases - Molecular
  • Diabetes
  • HIV Point of Care
  • i-STAT Business
  • COVID-19
  • Agilent Technologies
  • Recent Revenue History
    • Table 14-3: Agilent Revenues, 2017-2023 (million $)
  • Agilent in Genomics
  • Cytogenetic Analysis
  • Sequencing
  • Flow Cytometry
  • Companion Diagnostics - Dako
  • COVID-19
  • Becton, Dickinson and Company (BD)
  • Recent Revenue History
    • Table 14-4: BD Diagnostic Revenues, 2017-2023 (million $) FYE Sept 30
  • Cytology
  • Molecular Microbiology
  • Traditional Microbiology - ID/AST
  • Blood Culture
  • Hospital Acquired Infections
  • Blood Collection
  • Mass Spectrometry
  • COVID-19
  • bioMerieux Inc.
  • Recent Revenue History
    • Table 14-5: bioMerieux IVD Revenues, 2017-2023 (million $)
  • Traditional Microbiology
  • Blood Culture
  • Immunoassays
  • Mass Spectrometry
  • BioFire Diagnostics Business
  • COVID-19
  • Bio-Rad Laboratories, Inc.
  • Recent Revenue History
    • Table 14-6: Bio-Rad Diagnostics Revenues, 2017-2023 (million $)
  • Blood Bank
  • Immunoassays
  • COVID-19
  • Bruker Corporation
  • Recent Revenue History
    • Table 14-7: Bruker Revenue History Product Revenue, 2017-2023 ($ million)
  • Acquisitions and Collaborations
  • Mass Spectrometry
  • Microbiology
  • Molecular PCR
  • COVID-19
  • Danaher Corporation
  • Recent Revenue History
    • Table 14-8: Danaher Global IVD Diagnostic Sales, 2017-2023 (million $)
  • Dexcom
  • Recent Revenue History
    • Table 14-9: Dexcom IVD Diagnostic Sales, 2017-2023 (million $)
  • DiaSorin
  • Recent Revenue History
    • Table 14-10: DiaSorin Revenues, 2017-2023 (million $)
  • Immunoassays
  • Molecular
  • COVID-19
  • Exact Sciences
  • Recent Revenue History
    • Table 14-11: Exact Sciences Revenues, 2017-2023 (million $)
  • COVID-19
  • Hologic, Inc.
  • Recent Revenue History
    • Table 14-12: Hologic Revenues, 2017-2023 (million $)
  • PANTHER Molecular System
  • HIV Testing
  • Sexually Transmitted Infections
  • Infectious Diseases
  • Cytology
  • COVID-19
  • Illumina
  • Recent Revenue History
    • Table 14-13: Illumina Diagnostics Revenues, 2017-2023 (million $)
  • COVID-19
  • Instrument Laboratory/ Werfen
  • Expansion
  • Coagulation
  • Acute Care
  • Natera
  • Recent Revenue History
    • Table 14-14: Natera Revenue History 2017-2023 ($ million)
  • Prenatal Paternity Testing
  • QuidelOrtho Corporation
  • Recent Revenue History
    • Table 14-15: QuidelOrtho Revenue History 2018-2023 ($ million)
  • Immunoassays
  • Rapid Immunoassays
  • The Solana Business
  • Molecular - Savanna
  • Blood Bank
  • COVID-19
  • Revvity
    • Table 14-16: Revvity Revenue History 2021-2023 ($ million, estimated)
  • Roche Diagnostics
  • Recent Revenue History
    • Table 14-17: Roche Diagnostics IVD Revenues, 2017-2023 (million $)
  • Hematology
  • Core Lab
  • Immunoassays
  • HIV
  • Core Molecular
  • Digital PCR
  • Diabetes Care
  • Coagulation
  • cobas Liat System - POC
  • HPV
  • Blood Bank
  • Transplant Medicine
  • Cancer Companion Testing
  • COVID-19
  • Siemens Healthineers (Siemens)
  • Recent Revenue History
    • Table 14-18: Siemens Healthineers IVD Revenues, 2017-2023 (million $)
  • Immunoassays
  • Hematology
  • Molecular
  • Acute Care - POC
  • COVID-19
  • Sysmex Corporation
  • Recent Revenue History
    • Table 14-19: Sysmex IVD Revenues 2018-2023 (million $) FY March 31
  • Hematology
  • Coagulation
  • Urinalysis
  • Immunoassays
  • Precision Medicine / Companion Test Diagnostics
  • Oncology
  • COVID-19
  • Thermo Fisher Scientific Inc.
  • Recent Revenue History
    • Table 14-20: Thermo Fischer IVD Revenues, 2017-2023 (million $)
  • Immunoassays
  • Microbiology
  • Next Generation Sequencing
  • Molecular and qPCR
  • Mass Spectrometry
  • COVID-19
  • Werfen
  • Recent Revenue History
    • Table 14-21: Werfen IVD Revenues, 2017-2023 (million $)
  • Hematology and Coagulation
  • Autoimmunity

Contact Us